Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Coherus Oncology, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 205 | 188 | −17 |
| Shares | 80.3M | 77.9M | −2.44M (−3.0%) |
| Value | $1.17B | $1.08B | −$96.9M (−8.3%) |
New holders (21)
Institutions that held Coherus Oncology, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 116,257 | $1.61M | 0.01% |
| Jefferies Group LLC | 110,285 | $1.53M | 0.03% |
| Brandywine Global Investment Management, LLC | 75,819 | $1.05M | 0.01% |
| Amalgamated Bank | 34,760 | $481.0K | 0.00% |
| Glenmede Trust Co NA | 30,559 | $422.0K | 0.00% |
| Livforsakringsbolaget Skandia, Omsesidigt | 24,300 | $336.0K | 0.02% |
| Jump Financial, LLC | 23,900 | $331.0K | 0.03% |
| Point72 Hong Kong Ltd | 17,617 | $244.0K | 0.02% |
| Cambridge Investment Research Advisors, Inc. | 17,578 | $243.0K | 0.00% |
| TownSquare Capital, LLC | 14,733 | $201.0K | 0.01% |
| Gsa Capital Partners LLP | 12,453 | $172.0K | 0.02% |
| Caption Management, LLC | 12,000 | $167.0K | 0.01% |
| Amundi | 10,994 | $152.0K | 0.00% |
| HSBC Holdings PLC | 10,556 | $147.0K | 0.00% |
| ACT Capital Management, LLC | 6,500 | $90.0K | 0.05% |
| Banque Cantonale Vaudoise | 2,251 | $31.0K | 0.00% |
| Eagle Bay Advisors LLC | 1,921 | $28.0K | 0.02% |
| BBVA USA | 616 | $9.00K | 0.00% |
| Quantbot Technologies LP | 417 | $5.00K | 0.00% |
| Berman Capital Advisors, LLC | 267 | $3.00K | 0.00% |
| TD Capital Management LLC | 10 | $0 | 0.00% |
Sold out (38)
Institutions that held Coherus Oncology, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.